Merck & Co. (MRK) 10-K2018 FY Annual report

Filed: 27 Feb 19, 4:36pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. sophomore Bad

New words: Acellular, adjunct, Adsorbed, afflicted, Antelliq, Argentina, arm, ASC, ASCO, ASR, ASU, attenuated, auditor, axitinib, basket, BC, Beach, bilateral, birthday, body, border, Burling, Cavatak, ceftolozane, cert, cervical, clause, clawback, clearance, cloud, CNDA, coexistence, colistimethate, colistin, compel, conditionally, conjugate, context, coupon, Covington, CPS, cystectomy, cytotoxic, Czech, Delaware, Delstrigo, depict, diagnosed, directionally, dissolution, docetaxel, drove, ejection, embedded, endometrial, engineered, epidermal, ESMO, esophagogastric, fight, Francisco, Gastrointestinal, gefapixant, Genitourinary, glycaemic, Greece, Hamburg, handed, histology, Hong, immunocompromised, immunodeficiency, Inlyta, insomnia, intolerance, investee, invoice, invoiced, irinotecan, ix, JMHLW, kidney, Kong, leadership, Liaison, lymph, malignant, men, Meningococcal, mesothelioma, metronidazole, Mexican, Mizell, Monsanto, Nally, nephrotoxicity, Nike, NNRTI, node, nosocomial, onset, opt, orexin, Organisation, ORR, outlook, paclitaxel, payback, pet, Pifeltro, pilot, polymorphic, preserved, prompt, pull, rare, reactivation, Rebecca, Republic, resection, retailer, rosuvastatin, Rosuzet, salt, San, satisfied, satisfy, Scalibor, SCLC, shipment, shortly, sickle, sleep, Slovakia, somatic, sorafenib, Sovaldi, spent, Steven, sunitinib, suvorexant, switching, Symposium, tazobactam, toxicity, traceability, unaffected, unbudgeted, undergone, unresponsive, unsettled, vast, verification, vi, viii, vivo, waiting, wrongly, Zaire, ZVex

Removed: adam, adequately, Aerosol, aforementioned, air, alendronate, Allergan, amortizing, anacetrapib, anticipate, AQ, Aquaculture, Arcoxia, asthma, atypical, austerity, beta, bezlotoxumab, biopharmaceutical, BMS, broadly, buy, Byetta, calcitonin, calendar, cardiac, cessation, CETP, CGRP, chloride, cholesteryl, claimed, collect, collected, consummated, convertible, core, corticosteroid, coupled, Cozaar, declaration, delayed, dental, Department, devaluation, dihydrate, dismissal, Domestically, Dulera, educate, Elkton, ESI, ester, etoricoxib, extending, extraction, farm, federally, focusing, Follistim, follitropin, formalized, Fosamac, Gaynor, healing, heightened, hematological, Hib, holston, hydrochlorothiazide, Hyzaar, impose, influenzae, Inhalation, inhaled, Inspector, Inter, IPR, ipragliflozin, jaw, join, Kotobuki, leave, Lederle, losartan, male, Maryland, mg, mirian, montelukast, Mundipharma, myeloma, nasal, nationwide, NewLink, NGM, Noncompliance, notice, occurring, official, ONJ, Ono, ophthalmology, ordered, peptide, permanently, persistent, polio, positioned, postcombination, potassium, preexisting, principle, printed, proceed, proceeding, proximate, PSC, Puregon, Ratio, recommend, redeemed, refund, rejected, repatriated, requested, requesting, retiree, schechter, sexual, stake, Steering, suffered, supplement, surotomycin, testicular, Teva, tiered, tooth, ulcerative, unaudited, unconditionally, undergoing, unremitted, unspecified, USPTO, Venezuelan, Victoza, VZV, web, whooping, wide, writing, Zuellig

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated MRK transcripts

MRK similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

Section 1350

Certification of Chief Executive Officer

Pursuant to 18 U.S.C. Section 1350, the undersigned officer of Merck & Co., Inc. (the “Company”), hereby certifies that the Company’s Annual Report on Form 10-K for the year ended December 31, 2018 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Dated: February 27, 2019		/s/ Kenneth C. Frazier
		Name: KENNETH C. FRAZIER
		Title: Chairman, President and Chief Executive Officer